LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Home・Akcijų sąrašas・Sanofi

Sanofi

Uždarymo kaina

46.24 -0.49

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

45.85

Max

46.43

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-3.6B -801M
Pardavimai	-965M 12B
P/E Sektoriaus vid.	20.11 108.767
Dividendų pajamingumas	8.47
Pelno marža	-6.563
Darbuotojai	74,846
EBITDA	-391M 3.8B

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+24.84% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	8.47% 2.21%

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	143M 115B
Ankstesnė atidarymo kaina	46.73
Ankstesnė uždarymo kaina	46.24

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

51.665 / 52.38 Palaikymas ir pasipriešinimas

Sanofi Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-12 12:40; UTC

Pagrindinės rinkos jėgos

Sanofi Shares Fall After CEO Change

2026-01-29 11:35; UTC

Uždarbis

Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update

2026-01-29 07:01; UTC

Uždarbis

Sanofi to Launch $1.20 Billion Share Buyback

2025-12-24 11:40; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal -- Update

2026-02-24 14:00; UTC

Įsigijimai, susijungimai, perėmimai

This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug -- Barrons.com

2026-02-13 08:21; UTC

Rinkos pokalbiai

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

2026-02-12 15:20; UTC

Uždarbis

Sanofi Shares Fall After CEO Change -- Update

2026-02-10 14:07; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Set Out $2.2 Bln Cash Deal for Dynavax Late Last Year

2026-02-10 14:06; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Acquisition Includes Dynavax's Hepatitis B Vaccine, Shingles Vaccine Candidate

2026-02-10 14:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Completes Acquisition of Dynavax

2026-02-10 14:00; UTC

Įsigijimai, susijungimai, perėmimai

Press Release: Sanofi Completes The Acquisition Of Dynavax >SAN.FR

2026-02-06 12:35; UTC

Uždarbis

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

2026-01-29 13:00; UTC

Rinkos pokalbiai

Uždarbis

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

2026-01-29 06:30; UTC

Uždarbis

Sanofi 4Q Business EPS EUR1.53

2026-01-29 06:30; UTC

Uždarbis

Sanofi 4Q Sales EUR11.30B

2026-01-29 06:30; UTC

Uždarbis

Analysts Saw Sanofi 4Q Sales at EUR11.14B

2026-01-29 06:30; UTC

Uždarbis

Sanofi Expects 2026 Sales to Grow by High Single-Digit Percentage at CER

2026-01-29 06:30; UTC

Uždarbis

Sanofi Expects 2026 Business EPS at CER to Grow Slightly Faster Than Sales Before Share Buyback

2026-01-29 06:30; UTC

Uždarbis

Sanofi 4Q Business Operating Income EUR2.34B

2026-01-29 06:30; UTC

Uždarbis

Analysts Saw Sanofi 4Q Business Operating Income EUR2.37B

2026-01-29 06:30; UTC

Uždarbis

Sanofi Intends to Execute Share Buyback Program in 2026 of EUR1B

2026-01-29 06:30; UTC

Uždarbis

Sanofi Issues 2026 View

2026-01-23 11:25; UTC

Rinkos pokalbiai

Sanofi's Eczema Treatment Delivers Mixed Results Across Several Trials -- Market Talk

2026-01-16 17:03; UTC

Rinkos pokalbiai

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

2026-01-16 16:32; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

2026-01-12 19:24; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

2026-01-12 19:22; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

2025-12-31 08:49; UTC

Rinkos pokalbiai

Sanofi's Pipeline Weakness Likely to Hamper Growth -- Market Talk

2025-12-24 17:08; UTC

Įsigijimai, susijungimai, perėmimai

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

2025-12-24 12:59; UTC

Įsigijimai, susijungimai, perėmimai

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Sanofi Prognozė

Kainos tikslas

By TipRanks

24.84% į viršų

12 mėnesių prognozė

Vidutinis 59.5 USD 24.84%

Aukščiausias 62 USD

Žemiausias 57 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sanofi kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Sanofi akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

51.665 / 52.38Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.